Exdensur Depemokimab Application Scope

Exdensur (Depemokimab) is indicated as an add-on maintenance treatment for severe asthma with an eosinophilic phenotype in adults and adolescents aged 12 years and older whose disease is inadequately controlled with standard therapy.

Depemokimab Characteristics

Ingredients: Depemokimab – a human monoclonal antibody that targets interleukin-5 (IL-5), helping to reduce eosinophilic inflammation associated with severe asthma.
Properties: Sterile, preservative-free solution for subcutaneous injection containing a human monoclonal antibody targeting IL-5.
Packaging Specification: 100 mg/1 mL × 1 prefilled syringe
Storage: Store refrigerated at 2–8 °C; do not freeze; keep in original packaging to protect from light; do not shake.
Expiry Date: Typically 24–36 months under recommended storage conditions (depending on batch and regional regulatory approval).
Executive Standard: Drug registration standard approved by the regulatory authority.
Approval Number: Marketing authorization number (MA No.)
Date of Revision: Latest publicly available product information updates: 2025–2026 (following regulatory approvals).
Manufacturer: GlaxoSmithKline (GSK)

Guidelines for the Use of Exdensur

Dosage and Administration:
- Recommended Dose: 100 mg administered once every 26 weeks (approximately every 6 months) as add-on maintenance therapy.
- Administration: Subcutaneous injection. Administered by a healthcare professional or via approved autoinjector depending on local prescribing guidance.
- Missed Dose: If a dose is missed, administer as soon as possible and continue dosing every 26 weeks thereafter.
Adverse Reactions:
- Common Adverse Reactions: Common adverse reactions (≥4% reported in clinical trials) include upper respiratory tract infection, allergic rhinitis, influenza, arthralgia, pharyngitis, and injection site reactions.
- Serious Adverse Reactions: Serious adverse reactions may include hypersensitivity reactions such as anaphylaxis, potential complications related to parasitic infections, and worsening asthma if used inappropriately for the treatment of acute symptoms.
Contraindications: Known hypersensitivity to depemokimab or any component of the formulation.
Precautions:
- Not for treatment of acute asthma attacks or bronchospasm.
- Do not abruptly discontinue corticosteroids when initiating therapy.
- Patients with helminth infections should receive appropriate treatment prior to starting therapy.

Depemokimab Interactions

No clinically significant drug-drug interactions have been identified in current studies; however, concomitant use with immunomodulatory therapies should be evaluated by clinicians.

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
This content is for reference only. Prescription drugs must be used under a doctor’s guidance and purchased from authorized sources.